Affinage

NCR3

Natural cytotoxicity triggering receptor 3 · UniProt O14931

Audit flag: ungrounded claim
Length
201 aa
Mass
21.6 kDa
Annotated
2026-06-10
100 papers in source corpus 40 papers cited in narrative 40 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/8 claims corpus-supported (88%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NCR3 (NKp30) is a V-type immunoglobulin superfamily activating receptor selectively expressed on human NK cells that drives cytotoxicity, cytokine secretion, and dendritic-cell editing as a core natural cytotoxicity receptor (PMID:10562324, PMID:11828009). The receptor lacks intrinsic signaling motifs and instead associates non-covalently with CD3ζ chains, which are tyrosine-phosphorylated upon ligation (PMID:10562324); downstream signaling proceeds through PI3K/Akt (PMID:11385609), a Syk→NF-κB cascade (PMID:18025182), and Erk1/2 (PMID:22101078), and effector killing requires RAB27A-dependent granule exocytosis rather than the Vav1 route used by CD16 (PMID:17255357). Its principal activating tumor ligand is the B7-family protein B7-H6, which NKp30 engages through the F/C strands and CD loop of its Ig-like domain via an antibody-like interaction using both β-sheets of the V-domain (PMID:19528259, PMID:21422170, PMID:21444796); the released nuclear protein BAG-6/BAT3 is a second activating ligand bound at high affinity by a defined C-terminal dimeric fragment (PMID:18055229, PMID:24133212). NKp30 ligation also mediates recognition and killing of microbial targets including Plasmodium-infected erythrocytes, Cryptococcus/Candida, and filovirus-infected DCs (PMID:17436233, PMID:24139398, PMID:17381429). NKp30 function is suppressed at multiple levels: TGF-β1 transcriptionally downregulates surface receptor (PMID:12646700), viral evasion proteins HCMV pp65 and poxviral hemagglutinin block activation—pp65 by dissociating CD3ζ (PMID:15821739, PMID:21901096)—and tumor-derived soluble galectin-3 and shed B7-H6 antagonize signaling (PMID:25315772, PMID:24780758). B7-H6 ligand availability is itself controlled by c-Myc/N-Myc-driven transcription, HDAC-dependent histone acetylation at its promoter, and ADAM10/17 ectodomain shedding (PMID:27622013, PMID:23801635, PMID:24780758). Alternative splicing into immunostimulatory (NKp30a/b) versus immunosuppressive (NKp30c) isoforms differentially polarizes NK effector functions and correlates with neuroblastoma outcome (PMID:25877893). A functional NCR3 promoter polymorphism is associated with protection from primary Sjögren's syndrome, in which B7-H6 is expressed on salivary gland epithelium (PMID:23884468).

Mechanistic history

Synthesis pass · year-by-year structured walk · 28 steps
  1. 1999 High

    Established the existence and identity of NKp30 as a dedicated NK-restricted activating receptor, defining the molecular entity whose ligands and signaling would later be dissected.

    Evidence mAb generation, cDNA cloning, CD3ζ co-immunoprecipitation, and redirected killing/masking assays in human NK cells

    PMID:10562324

    Open questions at the time
    • No ligand identified at this stage
    • Downstream signaling pathway undefined
  2. 2001 High

    Defined the proximal signaling requirement, placing PI3K/Akt downstream of NKp30 engagement and linking it to lysis of antigen-presenting cells.

    Evidence Pharmacological PI3K inhibition and Akt phosphorylation Western blots in NK/APC co-cultures

    PMID:11385609

    Open questions at the time
    • Did not connect PI3K to a specific transcriptional or cytoskeletal output
    • Ligand on APCs unidentified
  3. 2002 High

    Identified NKp30 as the dominant trigger for NK editing of dendritic cells, establishing a physiological role in immune regulation beyond tumor killing.

    Evidence NK/DC co-culture cytotoxicity with receptor-specific mAb blocking and HLA masking

    PMID:11828009

    Open questions at the time
    • DC ligand for NKp30 not identified
    • Mechanism distinguishing immature vs mature DC susceptibility incomplete
  4. 2003 High

    Showed that NKp30 surface expression is transcriptionally tunable, identifying TGF-β1 as a suppressive regulator that abrogates DC killing.

    Evidence Flow cytometry, transcriptional analysis, and cytotoxicity assays with TGF-β1 treatment

    PMID:12646700

    Open questions at the time
    • Transcription factors mediating TGF-β1 effect not mapped
    • Differential tumor-line susceptibility unexplained
  5. 2005 High

    Distinguished NKp30's cytokine-producing function from its cytolytic function and showed it drives DC maturation via TNF-α/IFN-γ independent of killing.

    Evidence Cytokine neutralization, supernatant transfer, and perforin-deficient NK cell analysis

    PMID:15784725

    Open questions at the time
    • Signaling branch controlling cytokine vs cytotoxic output not resolved
  6. 2005 High

    Revealed a viral immune evasion mechanism, showing HCMV pp65 binds NKp30 and inhibits it by dissociating the CD3ζ signaling chain.

    Evidence Direct binding, co-IP, CD3ζ dissociation Western blots, and cytotoxicity assays

    PMID:15821739

    Open questions at the time
    • Structural basis of pp65/NKp30 interaction not determined
  7. 2007 High

    Identified BAT3/BAG-6 as a soluble tumor-derived activating ligand of NKp30 with in vivo relevance to tumor rejection.

    Evidence Pulldown with NKp30-Fc, binding assays, knockdown, and multiple myeloma in vivo model

    PMID:18055229

    Open questions at the time
    • Binding interface on NKp30 not yet mapped (resolved later in #23)
    • Relative contribution vs membrane ligands unclear
  8. 2007 High

    Mapped effector divergence among activating receptors, showing NKp30 cytotoxicity is RAB27A-dependent and Vav1-independent, unlike CD16.

    Evidence Griscelli syndrome type 2 patient NK cells and Vav1 phosphorylation analysis

    PMID:17255357

    Open questions at the time
    • Full proximal signaling adaptors between CD3ζ and RAB27A not enumerated
  9. 2007 High

    Established the canonical NF-κB arm of NKp30 signaling and placed Syk upstream of it.

    Evidence IκB degradation, EMSA, κB-GFP reporter, and Syk inhibition in NK cell lines

    PMID:18025182

    Open questions at the time
    • Link between NF-κB activation and specific effector genes not detailed
  10. 2007 Medium

    Extended NKp30 ligand recognition to microbial targets including Plasmodium-infected erythrocytes and filovirus-infected DCs.

    Evidence NKp30-Ig binding, DBL-1α peptide competition, siRNA knockdown, and perforin/granzyme assays

    PMID:17381429 PMID:17436233

    Open questions at the time
    • Single-lab findings with limited follow-up
    • Direct structural confirmation of DBL-1α/NKp30 binding lacking
  11. 2007 Medium

    Introduced and contested a heparan-sulfate ligand model, with glycosylation of NKp30 itself shown to gate HS binding.

    Evidence rNKp30-Fc binding to HS-modified cells, enzymatic HS removal, deglycosylation; opposing positive and negative results across labs

    PMID:15294952 PMID:15972650 PMID:18006589

    Open questions at the time
    • Whether HS is a genuine cellular ligand remains internally contradictory in the literature
    • Physiological relevance of recombinant-protein glycoforms unclear
  12. 2009 High

    Identified B7-H6 as a tumor-selective activating cell-surface ligand for NKp30, providing the canonical activating ligand of the receptor.

    Evidence NKp30-Fc binding screen, co-IP, NK activation/cytotoxicity, and normal-vs-tumor expression analysis

    PMID:19528259

    Open questions at the time
    • Structural mode of engagement not yet known
    • Regulation of B7-H6 expression undefined at this point
  13. 2009 Medium

    Identified a suppressive cellular context, with MDSCs from HCC patients inhibiting NK function through NKp30 in a contact-dependent manner.

    Evidence MDSC/NK co-culture with NKp30 blocking and functional readouts

    PMID:19551844

    Open questions at the time
    • Molecular ligand/mechanism on MDSCs not identified
    • Single-lab correlative system
  14. 2011 High

    Defined the structural basis of NKp30/B7-H6 recognition, revealing a unique antibody-like engagement using both β-sheets and identifying the F strand/C strand/CD loop binding region.

    Evidence X-ray crystallography of the complex and apo NKp30, peptide epitope mapping, mutagenesis, and solution binding

    PMID:21422170 PMID:21444796

    Open questions at the time
    • Did not address glycosylation- or oligomerization-dependent binding (later in #37)
  15. 2011 High

    Demonstrated a second viral evasion strategy, with poxviral hemagglutinin selectively blocking NKp30 (while stimulating NKp46).

    Evidence NCR-CD3ζ reporter cells, siRNA silencing of individual NCRs, and HA binding/cytotoxicity assays

    PMID:21901096

    Open questions at the time
    • Structural interface of HA/NKp30 not determined
  16. 2012 High

    Connected NKp30 signaling to the immune synapse and Erk1/2, and expanded its microbial recognition to fungal pathogens via PI3K-dependent killing.

    Evidence Confocal synapse imaging, Erk1/2 Western blots, unbiased fungal receptor screen, conjugate/perforin assays, IL-12 restoration

    PMID:22101078 PMID:24139398

    Open questions at the time
    • Direct fungal NKp30 ligand not molecularly defined
    • Synapse co-accumulation mechanism with LFA-1 unresolved
  17. 2012 High

    Defined NKp30's role on non-NK lymphocytes, showing engagement on Vδ1 γδ T cells drives CC-chemokine secretion that suppresses CCR5-tropic HIV-1.

    Evidence mAb engagement of Vδ1 T cells, gain/loss-of-function, chemokine ELISA, and HIV-1 replication assays

    PMID:22403253

    Open questions at the time
    • Whether the same receptor splicing/signaling applies in γδ T cells as in NK cells not addressed
  18. 2013 High

    Defined the minimal BAG-6 module sufficient for high-affinity NKp30 binding and inhibition, refining the structural basis of soluble-ligand antagonism.

    Evidence Domain truncation/fusion mapping, KD measurement, and NK functional assays

    PMID:24133212

    Open questions at the time
    • How membrane-bound vs soluble BAG-6 switches between activating and inhibitory outcomes not fully resolved
  19. 2013 High

    Established that B7-H6 ligand availability is dynamically regulated, by proinflammatory induction on myeloid cells and by HDAC-dependent epigenetic control at its promoter.

    Evidence TLR/cytokine stimulation of monocytes/neutrophils, soluble/exosomal B7-H6 detection, HDACi and HDAC2/3 knockdown, and ChIP at the B7-H6 promoter

    PMID:23687088 PMID:23801635

    Open questions at the time
    • Upstream signals coupling inflammation to B7-H6 transcription not fully mapped (Myc link added in #34)
  20. 2014 High

    Identified soluble galectin-3 as an inhibitory NKp30 ligand and ADAM10/17 shedding as a mechanism generating immunosuppressive soluble B7-H6.

    Evidence NKp30-Fc IP and SPR for galectin-3, knockdown/overexpression with xenografts; ADAM inhibition and siRNA with surface B7-H6 and NK activation readouts

    PMID:24780758 PMID:25315772

    Open questions at the time
    • Whether galectin-3 and B7-H6 compete for overlapping NKp30 surfaces unresolved
  21. 2015 High

    Established isoform-level control of NKp30 output, with NKp30a/b/c splice variants differentially polarizing NK function and predicting neuroblastoma outcome.

    Evidence RT-PCR isoform quantification, isoform-specific functional assays, and clinical correlation in three patient cohorts

    PMID:25877893

    Open questions at the time
    • Molecular signaling differences between isoform cytoplasmic tails not biochemically resolved
  22. 2015 High

    Linked NCR3 to human disease genetics and extended its activity to ILC2s, where B7-H6 engagement drives type 2 cytokines.

    Evidence NCR3 promoter polymorphism reporter assays and pSS association; ILC2 NKp30/B7-H6 stimulation with blocking and galectin-3 inhibition

    PMID:23884468 PMID:26582946

    Open questions at the time
    • Causal mechanism linking reduced NCR3 transcription to pSS protection not fully defined
    • ILC2 signaling pathway downstream of NKp30 not dissected
  23. 2015 Medium

    Documented chronic ligand-driven receptor downregulation as a tumor immune-escape mechanism, with B7-H6 on ovarian carcinoma suppressing tumor-associated NK function.

    Evidence Phenotyping of tumor-associated NK cells from peritoneal fluid and functional assays against B7-H6+ targets

    PMID:26137398

    Open questions at the time
    • Correlative patient data without direct causal manipulation
    • Mechanism of NKp30 downregulation not molecularly defined here
  24. 2016 High

    Identified c-Myc/N-Myc as direct transcriptional drivers of the NKp30 ligand B7-H6, connecting oncogenic transcription to NK immune recognition.

    Evidence B7-H6 promoter luciferase reporters, Myc ChIP, Myc inhibition/knockdown, and NK degranulation assays across tumor types

    PMID:27622013

    Open questions at the time
    • Interplay between Myc and HDAC control of B7-H6 not integrated
  25. 2017 Medium

    Extended NKp30/B7-H6 signaling to a leukemia microenvironment, where ILC2 activation feeds an immunosuppressive MDSC circuit.

    Evidence NKp30 blocking in APL patient samples, IL-13 secretion assays, and in vivo survival analysis

    PMID:28928446

    Open questions at the time
    • Single-lab pathway; relative contributions of NKp30 vs CRTH2 not separated
    • Direct causality of IL-13/MDSC axis incompletely established
  26. 2019 Medium

    Linked tumor B7-H6 exposure to a shift toward inhibitory NCR3 splice variants and receptor downmodulation in HCC NK cells.

    Evidence NK phenotyping, NCR3 isoform qPCR, NK/HCC co-culture, and B7-H6 siRNA knockdown

    PMID:30153337

    Open questions at the time
    • Mechanism coupling ligand exposure to splicing changes unknown
    • Single-lab study
  27. 2020 High

    Revealed that NKp30 oligomerization and ligand affinity are glycosylation-dependent, providing a structural switch for receptor function.

    Evidence Size-exclusion chromatography, enzymatic deglycosylation, and crystallography of glycosylated NKp30/B7-H6

    PMID:32708305

    Open questions at the time
    • Whether glycosylation-driven oligomerization operates on the NK cell surface in vivo not shown
  28. 2024 Medium

    Showed that IL-2 selectively maintains NKp30 expression and that immunostimulatory isoform overexpression can rescue cytokine-deprived NK dysfunction.

    Evidence IL-2 deprivation, NK92/NK92MI comparison, isoform overexpression, and in vivo xenograft clearance

    PMID:38698855

    Open questions at the time
    • Mechanism by which IL-2 maintains NKp30 not defined
    • Single-lab study

Open questions

Synthesis pass · forward-looking unresolved questions
  • How signaling, splice isoform composition, glycosylation-dependent oligomerization, and competing activating/inhibitory ligands are integrated to set the threshold of NKp30 activation on a single cell remains unresolved.
  • No unified model linking isoform tail to downstream PI3K/Syk/Erk branching
  • Whether HS is a bona fide cellular ligand unresolved across conflicting studies
  • Surface-relevance of glycan-driven oligomerization untested in primary NK cells

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 3 GO:0060089 molecular transducer activity 3 GO:0098772 molecular function regulator activity 3
Localization
GO:0005886 plasma membrane 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3
Partners
B7-H6BAG6CD247ITGALLGALS3PP65
Complex memberships
NKp30–CD3ζ receptor complex

Evidence

Reading pass · 40 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 NKp30 is a 30-kD activating receptor selectively expressed on all resting and activated human NK cells, belonging to the immunoglobulin superfamily with a single V-type domain and a charged transmembrane residue. NKp30 associates with CD3ζ chains that become tyrosine phosphorylated upon activation. NKp30 was identified as the product of the previously known 1C7 gene. mAb-mediated cross-linking induces strong NK activation; masking inhibits cytotoxicity against tumor and normal targets. Monoclonal antibody generation, molecular cloning of cDNA, co-immunoprecipitation with CD3ζ, redirected killing assays, masking assays The Journal of experimental medicine High 10562324
2001 NK cell-mediated lysis of autologous antigen-presenting cells is triggered by engagement of NKp30 and NKp46, and is dependent on phosphatidylinositol 3-kinase (PI-3K) signaling; PI-3K inhibitors LY294002 and wortmannin blocked both APC lysis and NKp30-triggered activation, and also reduced Akt/PKB phosphorylation downstream of NKp30 engagement. NK cell/APC co-culture cytotoxicity assays, mAb masking, pharmacological PI-3K inhibition, redirected killing assay, Western blot for Akt/PKB phosphorylation European journal of immunology High 11385609
2002 NK cells recognize immature dendritic cells (iDCs) and kill them primarily via the NKp30 receptor; the NKp30 activating signal (not NKp46 or NKp44) is the major trigger for this NK-mediated DC killing. Mature DCs are protected from lysis unless MHC class I inhibitory signaling is blocked. NK/DC co-culture cytotoxicity assays, mAb-mediated receptor blocking, antibody-mediated HLA-A,B,C masking The Journal of experimental medicine High 11828009
2003 TGF-β1 down-regulates NKp30 surface expression at the transcriptional level, which in turn profoundly inhibits NK-mediated killing of dendritic cells. NKp30 down-regulation by TGF-β1 does not equally affect killing of all tumor lines, reflecting differential receptor usage. Flow cytometry for surface receptor expression, transcriptional analysis (gene regulation), NK cytotoxicity assays with TGF-β1 treatment Proceedings of the National Academy of Sciences of the United States of America High 12646700
2005 NK cell-mediated induction of DC maturation is dependent on NKp30 engagement: NKp30 ligation causes NK cells to produce TNF-α and IFN-γ, which in turn promote DC maturation. Masking NKp30 with mAbs strongly reduces DC maturation. Analysis of perforin-deficient NK cells showed that NKp30 can drive cytokine-dependent DC maturation independently of direct killing. NK/DC co-culture with mAb blocking of NKp30, cytokine neutralization with anti-TNF-α antibodies, supernatant transfer assays, analysis of perforin-deficient NK cells Blood High 15784725
2005 The HCMV tegument protein pp65 directly binds NKp30 and inhibits NK cell cytotoxicity by causing dissociation of the associated CD3ζ signaling chain from NKp30, thereby reducing killing activity. Direct binding assays, co-immunoprecipitation of pp65 with NKp30, Western blot for CD3ζ dissociation, NK cytotoxicity assays Nature immunology High 15821739
2004 Membrane-associated heparan sulfate proteoglycans (HSPGs) on target cell surfaces are recognized by NKp30 (and NKp46); 6-O-sulfation and N-acetylation state of the glucosamine building unit affect this recognition. Tumor cells with reduced cell-surface heparan sulfate (via heparanase expression, CHO mutants, or glypican-1 knockdown) show reduced recognition and lysis by NK cells. Binding assays with recombinant NKp30-Fc fusion, NK cytotoxicity assays with heparan sulfate-deficient cell lines and enzymatic removal of HS, siRNA knockdown of glypican-1 Journal of immunology Medium 15294952
2005 A study using complete enzymatic removal of heparan sulfate (HS) from multiple cell lines demonstrated that HS glycosaminoglycans are NOT ligands for NKp30, as removal of HS did not affect rNKp30-Fc binding or NKp30-dependent NK killing of target cells. This result contradicts the HSPG-ligand model. Mammalian heparanase treatment to remove HS from cell surfaces, rNKp30-Fc binding assays, NK cytotoxicity assays with HS-deficient vs. HS-expressing cells Journal of immunology Medium 15972650
2007 The nuclear protein BAT3/BAG-6 is released from tumor cells as a soluble factor, directly binds NKp30, and engages NKp30 on NK cells to trigger NKp30-mediated cytotoxicity. BAT3 was necessary for tumor rejection in a multiple myeloma model. Pulldown/co-immunoprecipitation of BAT3 with NKp30-Fc fusion protein, direct binding assays, NK cytotoxicity assays with BAT3 blocking/knockdown, in vivo multiple myeloma model Immunity High 18055229
2009 B7-H6, a new member of the B7 family encoded by a previously unannotated gene, is a tumor cell surface ligand for NKp30 that triggers NKp30-mediated NK cell activation and cytotoxicity. B7-H6 is expressed on tumor cells but not detected in normal human tissues. Recombinant NKp30-Fc binding screen, co-immunoprecipitation, NK cell activation and cytotoxicity assays, expression analysis of normal vs. tumor tissues The Journal of experimental medicine High 19528259
2009 MDSCs from HCC patients inhibit autologous NK cell cytotoxicity and cytokine secretion in a cell-contact-dependent manner primarily through the NKp30 receptor on NK cells (not via arginase activity). In vitro co-culture of MDSCs and NK cells, mAb blocking of NKp30, cytotoxicity and cytokine secretion assays Hepatology Medium 19551844
2009 NKp30, NKp44, and NKp46 bind to different heparan sulfate/heparin sequences; NKp30 and NKp44 have approximately one order of magnitude higher affinity for synthetic HS/heparin than NKp46, and NCR binding to HS is relevant for binding to tumor cells and NK cell activation. Microarray with synthetic HS/heparin oligosaccharides, surface plasmon resonance binding assays Journal of proteome research Medium 19196184
2011 Crystal structure of NKp30 bound to its tumor ligand B7-H6 was determined. NKp30 is a member of the CD28 family (includes CTLA-4 and PD-1) but uniquely engages B7-H6 using both front and back β-sheets of its Ig-like domain, resulting in engagement via the side and face of the β-sandwich. B7-H6 contacts NKp30 through CDR-like loops of its V-like domain in an antibody-like interaction distinct from other B7 family complexes. X-ray crystallography of NKp30/B7-H6 complex The Journal of experimental medicine High 21422170
2011 Crystal structure of the extracellular domain of NKp30 was determined, revealing an I-type Ig-like fold structurally distinct from NKp44 and NKp46. Peptide epitope mapping of a blocking antibody identified a critical ligand-binding region involving the F strand, C strand, and CD loop. Solution binding studies showed the N-terminal domain of B7-H6 is sufficient for NKp30 recognition; mutations near the F strand affect B7-H6 binding. X-ray crystallography, peptide epitope mapping, solution binding assays, site-directed mutagenesis Proceedings of the National Academy of Sciences of the United States of America High 21444796
2007 The glycosylation state of recombinant NKp30 critically affects its ability to bind heparan sulfate; N-linked glycans on NKp30 can mask HS binding, and deglycosylation of improperly glycosylated recombinant NKp30 restores heparin/HS binding. Three N-glycosylation sites are present on NKp30, and differential glycosylation modulates ligand binding properties. Binding assays with six different recombinant NKp30 preparations, enzymatic deglycosylation (PNGase F treatment), direct heparin binding assays, NK cell activation assays Glycobiology Medium 18006589
2007 NKp30 ligation induces rapid activation of the canonical NF-κB pathway (IκB degradation, nuclear translocation of p65/p50 heterodimer) in NK cells within 30 minutes. This response was blocked by proteasome inhibitor MG132 and Syk inhibitor piceatannol, placing Syk upstream of NF-κB in the NKp30 signaling cascade. Immunoblotting for IκB degradation, EMSA with supershift for NF-κB subunit identification, fluorescence microscopy in single NK cells, κB-GFP reporter assay in NK92 cells, pharmacological inhibitors Journal of immunology High 18025182
2007 NKp30 is responsible for recognition and killing of Plasmodium falciparum-parasitized erythrocytes; NKp30-Ig fusion proteins and DBL-1α peptides block this interaction. The DBL-1α domain of PfEMP-1 on parasitized erythrocytes is a direct, specific ligand for NKp30, leading to perforin production and granzyme B release. NKp30-Ig fusion protein binding assays, DBL-1α peptide competition experiments, perforin and granzyme B measurement assays The Journal of infectious diseases Medium 17436233
2007 In filovirus-infected dendritic cells, NK cell lysis is mediated through NKp30, as demonstrated by gene expression knockdown studies that directly linked NK lysis of infected DCs to NKp30 upregulation; perforin and CD95L (FasL) mediate the killing. Gene expression knockdown (siRNA), NK/DC cytotoxicity assays with infected vs. uninfected DCs, cytokine production measurement Cellular microbiology Medium 17381429
2008 In uterine decidual NK cells (dNK), NKp30 (but not NKp46) engagement triggers production of IFN-γ, TNF-α, MIP-1α, MIP-1β, and GM-CSF, whereas NKp46 (but not NKp30) engagement induces calcium mobilization, perforin polarization, granule exocytosis, and cytolytic activity. This demonstrates a differential, receptor-specific functional split in dNK cells. Flow cytometry for receptor expression, mAb-specific receptor engagement assays, calcium mobilization assays, granule exocytosis, cytokine measurement, cytotoxicity assays Journal of immunology High 18713971
2011 Poxviral hemagglutinin (HA) from vaccinia virus and ectromelia virus is a ligand for NKp30; HA present on VV-infected cells or as soluble protein blocks NKp30-triggered NK cell activation (while stimulating NKp46), representing an immune escape mechanism. Using NK cells with selectively silenced NKp30 expression (NCR-CD3ζ reporter cells), HA was shown to specifically block NKp30-mediated activation. NKp30 reporter cell assays (NCR-CD3ζ), siRNA silencing of individual NCRs, binding assays with recombinant HA, NK cytotoxicity assays PLoS pathogens High 21901096
2012 NKp30-mediated signaling activates the Erk1/2 signaling pathway in NK cells upon contact with tumor target cells; NKp30 blockade decreases Erk1/2 phosphorylation, inhibits degranulation, cytotoxicity, and cytokine secretion but does not affect NK-target cell conjugation. NKp30 and LFA-1 co-accumulate at the NK immune synapse interface with tumor cells. Confocal microscopy for synapse formation, mAb blocking of NKp30, Western blot for Erk1/2 phosphorylation, degranulation and cytotoxicity assays Immunological investigations Medium 22101078
2012 NKp30 is responsible for recognition and killing of fungal pathogens Cryptococcus and Candida by NK cells; NKp30 was required for NK cell-fungal conjugate formation, PI3K signaling, and perforin release. IL-12 restored NKp30 expression and fungal killing in HIV-infected patients with diminished NKp30. Unbiased receptor identification screen, blocking antibodies, NK-fungal conjugate formation assays, PI3K signaling assays, perforin release assays, IL-12 restoration experiments Cell host & microbe High 24139398
2012 The stalk domain of NKp30 is an important module for ligand recognition and related signaling; mutational analysis of NKp30 showed differential binding affinities and signaling capacities for mono-, di-, or triglycosylated NKp30, suggesting that N-glycosylation degree provides a switch to modulate NKp30 ligand binding properties. NKp30-hIgG1-Fc fusion proteins with stalk region mutations, N-glycosylation site mutagenesis, binding assays, signaling assays The Journal of biological chemistry Medium 22807449
2013 A 250-amino acid C-terminal fragment of BAG-6 (BAG-6(686-936)) forms a noncovalent dimer and is sufficient for high-affinity NKp30 binding (KD <100 nM) and inhibition of NKp30-dependent NK cell signaling, IFN-γ release, and degranulation in the presence of tumor target cells. Domain mapping by truncation/fusion constructs, binding assays (KD measurement), NK cell functional assays (IFN-γ, degranulation), co-culture with tumor cells The Journal of biological chemistry High 24133212
2013 B7-H6 is induced on non-transformed cells (proinflammatory CD14+CD16+ monocytes and neutrophils) upon TLR ligand stimulation or proinflammatory cytokines (IL-1β, TNF-α), producing both membrane-bound and soluble forms. In vivo, B7-H6 is expressed on monocytes during sepsis and soluble B7-H6 is associated with exosomal fractions in gram-negative sepsis. In vitro stimulation of monocytes/neutrophils with TLR ligands and cytokines, flow cytometry for surface expression, ELISA for soluble form, fractionation for exosomal association, in vivo patient serum analysis Blood Medium 23687088
2013 B7-H6 surface expression on tumor cells is downregulated by histone deacetylase inhibitors (pan- or class I HDACi) and by siRNA-mediated knockdown of HDAC2 or HDAC3, correlating with reduced histone acetylation at the B7-H6 promoter. This B7-H6 downregulation reduces NKp30-dependent NK effector functions. Pharmacological HDACi treatment, siRNA knockdown of HDAC isoforms, B7-H6 reporter assays, chromatin immunoprecipitation (ChIP) at B7-H6 promoter, NK cell functional assays Blood High 23801635
2014 Soluble Galectin-3 released from tumor cells directly binds NKp30 (confirmed by NKp30-Fc immunoprecipitation and surface plasmon resonance), and this interaction specifically inhibits NKp30-mediated (but not NKG2D-mediated) NK cell cytolysis and CD107a expression. Galectin-3 knockdown in tumor cells increased NK lysis; Galectin-3 overexpression reduced lysis in vitro and in vivo. NKp30-Fc immunoprecipitation, surface plasmon resonance binding assay, NK cytotoxicity assays with recombinant Gal-3, shRNA knockdown and overexpression, xenograft mouse model The Journal of biological chemistry High 25315772
2014 Tumor cells shed B7-H6 by ectodomain cleavage mediated by ADAM10 and ADAM17 metalloproteases; pharmacological inhibition or siRNA knockdown of ADAM10/17 increases cell-surface B7-H6 and enhances NKp30-mediated NK activation. Soluble B7-H6 is elevated in serum of melanoma patients. ADAM metalloprotease inhibitors, siRNA knockdown of ADAM10/ADAM17, flow cytometry for surface B7-H6, NK cell activation assays, patient serum ELISA Cancer research High 24780758
2007 NKp44 (but not NKp30) recognizes hemagglutinins of influenza virus and Sendai virus; NKp30 does not bind viral hemagglutinins. This establishes a specificity distinction among natural cytotoxicity receptors. Binding assays with HA-expressing cells, NK cell killing assays with HA-expressing targets, receptor-specific mAb blocking European journal of immunology Medium 11536166
2007 NKp30-mediated cytotoxicity is dependent on RAB27A (defective in Griscelli syndrome), whereas CD16-mediated killing is RAB27A independent. NKp30 engagement does not lead to Vav1 phosphorylation (unlike CD16), revealing a functional dichotomy in signaling pathways downstream of different NK activating receptors. Analysis of NK cells from a GS type 2 patient with RAB27A mutation, redirected killing assays, Western blotting for Vav1 phosphorylation after receptor-specific stimulation Blood High 17255357
2012 NKp30 engagement on Vδ1 γδ T cells triggers production of high levels of CCL3/MIP-1α, CCL4/MIP-1β, and CCL5/RANTES (but not CXCL12), and this NKp30-induced CC-chemokine secretion suppresses replication of a CCR5-tropic strain of HIV-1 in CD4+/CCR5+ cells. mAb-mediated NKp30 engagement on Vδ1 T cells, gain-of-function and loss-of-function experiments, ELISA for chemokine production, HIV-1 replication assay in PM1 cell lines Blood High 22403253
2015 B7-H6 expressed on ovarian carcinoma cells or present as soluble form induces chronic NKp30 downregulation on tumor-associated NK cells, impairing IFN-γ production and cytolytic function specifically against B7-H6-expressing targets. Phenotypic analysis of tumor-associated NK cells from peritoneal fluids, flow cytometry for NKp30 and B7-H6 expression, NK cell functional assays Oncoimmunology Medium 26137398
2015 NKp30 is expressed as three alternatively spliced isoforms (NKp30a, NKp30b, NKp30c) with different intracellular domains; these isoforms differentially polarize NK cell effector functions (immunostimulatory vs. immunosuppressive cytokine profiles). The balance of isoforms correlates with clinical outcomes in neuroblastoma patients. RT-PCR isoform quantification in patient NK cells, NK cell functional assays (cytokine profiles per isoform composition), clinical correlation in 196 patient cohort (3 independent cohorts) Science translational medicine High 25877893
2015 The NKp30 ligand B7-H6 is expressed on salivary gland epithelial cells in primary Sjögren's syndrome (pSS), and a promoter polymorphism (rs11575837, G>A) in NCR3/NKp30 is associated with reduced gene transcription/function and protection from pSS. Circulating NKp30 levels correlate with NKp30-dependent (not CD16-dependent) IFN-γ secretion. Case-control genetic association study, NKp30 promoter reporter assays (rs11575837 functional characterization), NK cell functional assays (receptor-specific stimulation), immunohistochemistry of salivary glands for B7-H6 Science translational medicine High 23884468
2016 The proto-oncogene c-Myc (and N-Myc) directly drives B7-H6 expression in tumor cells through a functional Myc-binding site in the B7-H6 promoter. Pharmacological inhibition or siRNA/shRNA knockdown of c-Myc or N-Myc significantly decreased B7-H6 expression, and Myc inhibition impaired NKp30-mediated degranulation of NK cells. Luciferase reporter assays with B7-H6 promoter, chromatin immunoprecipitation (ChIP) for Myc binding, pharmacological Myc inhibitors, siRNA/shRNA knockdown of c-Myc and N-Myc, NK cell degranulation assays Oncoimmunology High 27622013
2017 In acute promyelocytic leukemia, ILC2s express functional NKp30 and are activated via NKp30/B7-H6 interaction (along with CRTH2/PGD2). NKp30-activated ILC2s secrete IL-13 which activates monocytic MDSCs; blocking NKp30 partially restores ILC2 and MDSC levels and increases survival. Flow cytometry for ILC2 NKp30 expression, NKp30-blocking experiments in APL patient samples, IL-13 secretion assays, in vivo survival analysis after pathway blockade Nature communications Medium 28928446
2015 ILC2s express functional NKp30; engagement of NKp30 with its cognate ligand B7-H6 induces rapid production of type 2 cytokines by ILC2s, which can be blocked by NKp30-blocking antibody or the inhibitory ligand galectin-3. B7-H6 expression is upregulated in lesional skin of atopic dermatitis patients and by proinflammatory cytokines on keratinocytes. Flow cytometry for NKp30 on ILC2s, NKp30/B7-H6 stimulation assays, blocking antibody experiments, galectin-3 inhibition, ILC2 cytokine measurement Journal of immunology Medium 26582946
2020 NKp30 oligomerization depends on its N-glycosylation: NKp30 forms oligomers when expressed with simple N-glycans (in HEK293S GnTI- cells) but is detected only as monomers after enzymatic deglycosylation. A crystal structure of glycosylated NKp30 in complex with B7-H6 reveals a new glycosylation-induced mode of NKp30 dimerization; the stalk region also affects oligomerization and ligand affinity. Size exclusion chromatography for oligomeric state, enzymatic deglycosylation, X-ray crystallography of glycosylated NKp30/B7-H6 complex, binding assays Cancers High 32708305
2024 IL-2 deprivation preferentially downregulates NKp30 (but not NKp46) expression on NK cells, impairing NKp30-dependent cytotoxicity against B7-H6-expressing leukemia cells. Ectopic overexpression of immunostimulatory NKp30 isoforms (NKp30a or NKp30b) overcomes this IL-2 deficiency-mediated dysfunction, and NKp30a overexpression improved tumor clearance in vivo without IL-2 supplementation. IL-2 deprivation experiments, NK92 and IL-2-producing NK92MI cell comparison, ectopic NKp30 isoform overexpression, in vitro cytotoxicity assays, in vivo xenograft THP-1 clearance model Frontiers in immunology Medium 38698855
2019 In HCC patients, NKp30-positive NK cells show a reduced expression of NCR3 immunostimulatory splice variants and increased inhibitory variant expression, resulting in deficient NKp30-mediated function. Exposure of NK cells to B7-H6-expressing HCC cells downmodulates NKp30 expression, and siRNA knockdown of B7-H6 prevents this downmodulation. NK cell phenotyping by flow cytometry, NCR3 isoform qPCR, NK cell functional assays, in vitro NK/HCC cell co-culture, siRNA knockdown of B7-H6 Hepatology Medium 30153337

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. The Journal of experimental medicine 740 11828009
1999 Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. The Journal of experimental medicine 606 10562324
2003 Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 583 12646700
2009 The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. The Journal of experimental medicine 548 19528259
2009 Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (Baltimore, Md.) 539 19551844
2001 Recognition of viral hemagglutinins by NKp44 but not by NKp30. European journal of immunology 308 11536166
2005 NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 302 15784725
2005 Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nature immunology 285 15821739
2007 Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 272 18055229
2003 The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). European journal of immunology 251 12938217
2017 Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature communications 205 28928446
2011 Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 190 21633088
2014 Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer research 172 24780758
2009 Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC cancer 171 19531227
2012 NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature medicine 168 23178246
2015 B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology 153 26137398
2009 Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. Journal of proteome research 132 19196184
2015 Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Science translational medicine 124 25877893
2005 Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. Journal of immunology (Baltimore, Md. : 1950) 122 16272287
2013 Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 120 23687088
2013 Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 114 23801635
2012 An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. Journal of immunology (Baltimore, Md. : 1950) 114 22851709
2004 Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. Journal of immunology (Baltimore, Md. : 1950) 114 15294952
2014 Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. The Journal of biological chemistry 111 25315772
2008 Critical and differential roles of NKp46- and NKp30-activating receptors expressed by uterine NK cells in early pregnancy. Journal of immunology (Baltimore, Md. : 1950) 111 18713971
2001 NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. European journal of immunology 110 11385609
2010 Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance. Journal of hepatology 106 21168454
2018 Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer. Journal of immunology research 104 30255106
2013 NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Science translational medicine 101 23884468
2011 Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. The Journal of experimental medicine 100 21422170
2010 Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (Baltimore, Md.) 97 20812318
2013 The NK receptor NKp30 mediates direct fungal recognition and killing and is diminished in NK cells from HIV-infected patients. Cell host & microbe 94 24139398
2012 Engagement of NKp30 on Vδ1 T cells induces the production of CCL3, CCL4, and CCL5 and suppresses HIV-1 replication. Blood 93 22403253
2011 B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cellular and molecular life sciences : CMLS 90 21877119
2011 Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS pathogens 89 21901096
2015 Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production. Journal of immunology (Baltimore, Md. : 1950) 80 26582946
2015 Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6. The Journal of biological chemistry 79 26472927
2007 Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. PloS one 79 18092004
2007 A Duffy binding-like domain is involved in the NKp30-mediated recognition of Plasmodium falciparum-parasitized erythrocytes by natural killer cells. The Journal of infectious diseases 71 17436233
2011 Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. European journal of immunology 69 21695691
2012 Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC. Immunogenetics 66 22488247
2005 NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli. Molecular biology and evolution 66 15872155
2005 Effects of prolactin and cortisol on natural killer (NK) cell surface expression and function of human natural cytotoxicity receptors (NKp46, NKp44 and NKp30). Clinical and experimental immunology 63 15654827
2018 Distinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential. Proceedings of the National Academy of Sciences of the United States of America 62 29895693
2019 Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. Hepatology (Baltimore, Md.) 59 30153337
2001 Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca fascicularis NK cells. European journal of immunology 58 11745374
2011 Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proceedings of the National Academy of Sciences of the United States of America 57 21444796
2017 Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells. Journal of virology 50 28956765
2007 Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology 49 18006589
2016 The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology 48 27622013
2005 LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma, LPS and microbial infection. Immunogenetics 48 16362817
2012 Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) 47 23066150
2016 NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncoimmunology 46 28197361
2013 Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. Journal of immunology (Baltimore, Md. : 1950) 46 23960237
2020 NKp30 - A prospective target for new cancer immunotherapy strategies. British journal of pharmacology 44 32737988
2015 Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age. Biogerontology 44 25991472
2020 Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement. Journal of immunology (Baltimore, Md. : 1950) 40 33268483
2008 Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. Journal of immunology (Baltimore, Md. : 1950) 40 18802053
2007 NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cellular microbiology 39 17381429
2012 The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. The Journal of biological chemistry 38 22807449
2013 A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells. The Journal of biological chemistry 35 24133212
2019 Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. Oncology research and treatment 34 30870839
2016 Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. Journal of immunology (Baltimore, Md. : 1950) 33 27511738
2015 HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. Oncotarget 33 26392331
2002 Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population. Genes and immunity 33 12486606
2013 Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. Immunology letters 31 23538009
2005 Evidence that the cellular ligand for the human NK cell activation receptor NKp30 is not a heparan sulfate glycosaminoglycan. Journal of immunology (Baltimore, Md. : 1950) 30 15972650
2022 Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release. Journal of immunology (Baltimore, Md. : 1950) 29 36104113
2015 Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology 29 26942070
2007 NKp30 ligation induces rapid activation of the canonical NF-kappaB pathway in NK cells. Journal of immunology (Baltimore, Md. : 1950) 29 18025182
2021 Influenza A Virus Hemagglutinin and Other Pathogen Glycoprotein Interactions with NK Cell Natural Cytotoxicity Receptors NKp46, NKp44, and NKp30. Viruses 26 33494528
2016 Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy. Critical reviews in immunology 25 28845754
2015 NKp30 isoforms in patients with chronic hepatitis C virus infection. Immunology 24 26094914
2021 Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles. International journal of molecular sciences 23 33671836
2016 NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution. Oncoimmunology 23 28123867
2020 PET Imaging of the Natural Killer Cell Activation Receptor NKp30. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 22 32532927
2007 Differential NKp30 inducibility in chimpanzee NK cells and conserved NK cell phenotype and function in long-term HIV-1-infected animals. Journal of immunology (Baltimore, Md. : 1950) 22 17237420
2020 Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its N-Glycosylation. Cancers 20 32708305
2018 Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1. Journal of immunology (Baltimore, Md. : 1950) 20 30120122
2017 Natural Killer Cells from the Subcutaneous Adipose Tissue Underexpress the NKp30 and NKp44 in Obese Persons and Are Less Active against Major Histocompatibility Complex Class I Non-Expressing Neoplastic Cells. Frontiers in immunology 20 29163547
2017 Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy. Immunobiology 19 29055565
2015 Coevolution of MHC genes (LMP/TAP/class Ia, NKT-class Ib, NKp30-B7H6): lessons from cold-blooded vertebrates. Immunological reviews 19 26284468
2007 NK cytotoxicity mediated by CD16 but not by NKp30 is functional in Griscelli syndrome. Blood 19 17255357
2006 Association analyses of NCR3 polymorphisms with P. falciparum mild malaria. Microbes and infection 19 17208487
2021 NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. Frontiers in immunology 18 34594326
2015 First Trimester Pregnancy Loss and the Expression of Alternatively Spliced NKp30 Isoforms in Maternal Blood and Placental Tissue. Frontiers in immunology 18 26082773
2013 Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 18 23802087
2024 Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers. mAbs 17 38372053
2016 NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. Scientific reports 17 27941937
2020 B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines. BMC cancer 16 33172426
2016 NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint. Oncotarget 15 27765926
2015 NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. PloS one 15 26241657
2009 Analysis of NK cell/DC interaction in NK-type lymphoproliferative disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Experimental hematology 15 19580844
2006 NKp30 is a functional activation receptor on a subset of rat natural killer cells. European journal of immunology 15 16821237
2021 Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30. Cancer immunology, immunotherapy : CII 14 34046711
2019 B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape. AIDS (London, England) 14 30325780
2016 Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30. Journal of molecular biology 14 27663271
2000 Expression and cellular localization of the protein encoded by the 1C7 gene: a recently described component of the MHC. Immunogenetics 14 10941844
2024 Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression. Frontiers in immunology 13 38698855
2012 Important role for NKp30 in synapse formation and activation of NK cells. Immunological investigations 13 22221078

Missed literature

Know a paper Affinage missed for NCR3? Flag it for the maintainers and the community.

No submissions yet.